New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
Study Presented at the 71st Annual American College of Cardiology Meeting
Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions and Expo in Washington, DC. Study data showed that Daxor’s BVA-100 test was uniquely able to measure the intravascular congestion of heart failure patients, a key metric that is targeted to improve their outcomes. A wide array of common proxy markers and clinical tools of assessment were also analyzed and shown to be wholly ineffective at making a comparative clinically actionable result, despite current common usage in many hospitals.
The study titled, “Intravascular Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients Hospitalized for Heart Failure,” assessed the relationship between blood volume, resting, and stress cardiovascular pressures in worsening heart failure (HF). Patients presenting to the hospital or outpatient clinic with clinical worsening HF underwent blood volume analysis measured with Daxor’s BVA-100 diagnostic blood test, right heart catheterization, provocative testing including blood pressure measurement, leg raises, breathing techniques, and patient symptoms and physical exam findings.
The study results showed little to no correlation between patient symptoms, physical exam or cardiac pressures as compared to direct blood volume measures. Vishal N. Rao, M.D., MPH, lead investigator of the study, concluded, “Blood volumes did not correlate with intracardiac pressures at rest or during provocative testing. Examination and hemodynamic metrics of vascular compliance are insufficient surrogates of measured blood volume in worsening HF.”
“More than 6 million Americans suffer from heart failure, one of the most prevalent, complex, and deadly diseases leading to nearly 1 million deaths and 1 million hospitalizations annually,” said Michael Feldschuh, CEO of Daxor Corporation. “These results show why patients managed with our unique diagnostic test have substantially better outcomes and why our test utilizes the gold standard methodology for accuracy. This study in the crucial area of worsening HF adds to the growing body of evidence that pressure measurements are not adequate substitutes for direct measurements of circulating volume. Our test informs clinicians with precise information to help manage and treat volume derangements in complex HF patients, enabling substantial improvements in mortality reduction, hospital readmission, and costs as demonstrated in previous studies.”
About Daxor Corporation
(Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at .
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
